Please try another search
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Name | Age | Since | Title |
---|---|---|---|
George M. Lasezkay | 71 | 2017 | President, CEO & Director |
Christy L. Shaffer | 65 | 2012 | Independent Director |
William D. Humphries | 57 | 2012 | Independent Director |
Richard J. Croarkin | 69 | 2016 | Independent Director |
Benjamin R. Yerxa | 57 | 2022 | Independent Director |
Jeffrey L. Edwards | 62 | 2018 | Independent Director |
Clay Bernardin Thorp | 55 | 2012 | Independent Chair of the Board |
Carl D. Regillo | - | 2020 | Member of Scientific Advisory Board |
Nancy June Hutson | 74 | 2020 | Independent Director |
David M. Brown | - | 2020 | Member of Scientific Advisory Board |
David S. Boyer | - | 2020 | Member of Scientific Advisory Board |
Arshad M. Khanani | - | 2023 | Member of Scientific Advisory Board |
Lejla Vajzovic | - | 2023 | Member of Scientific Advisory Board |
Thomas A. Ciulla | 59 | 2018 | Chairman of Scientific Advisory Board |
Anthony S. Gibney | 53 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review